Payment overview · 2025
General Payments
$241.30
11 reported records · 9 companies
Healthcare provider profile · identity verified
Ahmad M Ahmad, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DETROIT, MI · NPI 1992048607
Verified facts
What the public records show
CMS Open Payments records show Ahmad M Ahmad, MD received $241.30 in general payments during 2025 across 11 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.98 | 20.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.95 | 15.7% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $34.61 | 14.3% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $29.79 | 12.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.31 | 10.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.23 | 6.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.15 | 6.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.13 | 6.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.15 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $241.30 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $34.61 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $34.61 | 1 | 2025 |
Source payment records
|
|||||
| CEREBASE Normalized: cerebase |
Device | DePuy Synthes Sales Inc. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 394 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
394 | 112 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 196 |
| Eliquis | Apixaban | 394 | 112 |
| Gabapentin | Gabapentin | 319 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 291 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 94 |
| Furosemide | Furosemide | 233 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 107 |
| Lisinopril | Lisinopril | 167 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 77 |
| Carvedilol | Carvedilol | 141 | 62 |
| Omeprazole | Omeprazole | 139 | 60 |
| Losartan Potassium | Losartan Potassium | 134 | 66 |
| Sertraline Hcl | Sertraline Hcl | 134 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 62 |
| Baclofen | Baclofen | 100 | 15 |
| Metformin Hcl | Metformin Hcl | 98 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 47 |
| Levetiracetam | Levetiracetam | 95 | 31 |
| Tramadol Hcl | Tramadol Hcl | 95 | 32 |
| Donepezil Hcl | Donepezil Hcl | 93 | 33 |
| Trazodone Hcl | Trazodone Hcl | 92 | 33 |
| Simvastatin | Simvastatin | 91 | 30 |
| Midodrine Hcl | Midodrine Hcl | 89 | 42 |
| Methocarbamol | Methocarbamol | 87 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 28 |
| Memantine Hcl | Memantine Hcl | 77 | 21 |
| Mirtazapine | Mirtazapine | 77 | 22 |
| Xarelto | Rivaroxaban | 77 | 13 |
| Bumetanide | Bumetanide | 73 | 31 |
| Entresto | Sacubitril/Valsartan | 73 | 16 |
| Allopurinol | Allopurinol | 70 | 20 |
| Potassium Chloride | Potassium Chloride | 67 | 38 |
| Methylprednisolone | Methylprednisolone | 65 | 63 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 20 |
| Lorazepam | Lorazepam | 58 | 16 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Finasteride | Finasteride | 53 | 19 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 36 |
| Enulose | Lactulose | 48 | 15 |
| Jardiance | Empagliflozin | 48 | 18 |
| Alprazolam | Alprazolam | 47 | 22 |
| Levofloxacin | Levofloxacin | 47 | 44 |
| Nifedipine Er | Nifedipine | 47 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Prednisone | Prednisone | 45 | 27 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Risperidone | Risperidone | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 25 |
| Famotidine | Famotidine | 39 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 23 |
| Metronidazole | Metronidazole | 33 | 27 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 25 |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 15 |
| Clonidine Hcl | Clonidine Hcl | 30 | 13 |
| Colchicine | Colchicine | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 23 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Olanzapine | Olanzapine | 26 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 19 |
| Digoxin | Digoxin | 25 | 13 |
| Latanoprost | Latanoprost | 25 | 12 |
| Ondansetron Odt | Ondansetron | 25 | 16 |
| Sucralfate | Sucralfate | 25 | 21 |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 15 |
| Clobazam | Clobazam | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | 12 |
| Ezetimibe | Ezetimibe | 24 | 12 |
| Insulin Lispro | Insulin Lispro | 23 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Megestrol Acetate | Megestrol Acetate | 23 | 16 |
| Atenolol | Atenolol | 22 | 12 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Nyamyc | Nystatin | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | 11 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 15 |
| Silodosin | Silodosin | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Brilinta | Ticagrelor | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Diazepam | Diazepam | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241.30 · 11 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Auvelity, CAPVAXIVE, CEREBASE, ELIQUIS, GARDASIL 9, JARDIANCE, NURTEC ODT, OPSUMIT, QULIPTA, UBRELVY, UPTRAVI, XIFAXAN, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error